Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, shares his perspectives on personalizing therapy in patients with multiple myeloma. According to Prof. Morgan, therapy choice should be based on high-risk or low-risk genetic factors in addition to the patient’s desires, performance status, and clinical status. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.